Full-Life Technologies

Full-Life Technologies Limited is a fully integrated global radiopharmaceuticals company focused on the research, development, production, and commercialization of radiotherapeutic drugs for cancer treatment. The company owns the entire value chain for radiopharmaceuticals — from isotope production and chemistry through clinical development and logistics — enabling it to deliver novel targeted radionuclide therapies directly to patients. Full-Life's pipeline includes compounds that attach radionuclides to targeting vectors (peptides, small molecules, and single-domain antibodies) to deliver therapeutic payloads directly to tumors. Founded in 2021, the company operates across Belgium, Germany, and China, with a state-of-the-art manufacturing facility in Gembloux, Belgium, and operations in Shanghai and Heidelberg. The company has raised over $227 million in financing and counts Vivo Capital and Junson Capital among its investors.